FDA Mandates Warnings for GLP-1 Eye Danger

Manufacturers of widely used weight loss medications, including Ozempic and Zepbound, must now add warnings regarding a rare but serious eye condition. The U.S. Food and Drug Administration (FDA) announced this requirement on Monday. The condition, identified as non-arteritic anterior ischemic optic neuropathy (NAION), has been linked to an increased risk for individuals taking these GLP-1 drugs. NAION can potentially lead to permanent vision loss. This advisory comes as approximately 28 million Americans are reportedly using these popular weight loss drugs, according to a July Gallup poll. The updated labeling aims to inform patients and healthcare providers about this potential risk associated with GLP-1 medications.